

***Discovery of Potent and Orally Bioavailable BACE-1  
Inhibitors for the Treatment of Alzheimer's Disease***

**Dr. Oscar Delgado**

**Janssen Research and Development (Spain)**

**Thursday 4th September, 2014. ICIQ Auditorium, 12 p.m.**

**Professional Career**



Oscar Delgado was born in Santa Cruz de Tenerife in 1977. He studied chemistry at the Universidad de Sevilla (1995-2000). Then he obtained his PhD from Cambridge University in 2004, working on the total synthesis of marine natural products such as dictyostatin, under the supervision of Prof. Ian Paterson. After a postdoctoral stay in the group of Prof. Thorsten Bach at the Technische Universität München (2004-2006), where he completed the total synthesis of the thiopeptide antibiotic GE2270A, he joined the Neuroscience Medicinal Chemistry team of Janssen in Toledo. The current focus of the group is the discovery of disease modifying treatments for neurodegenerative pathologies. He is currently responsible for several neuroscience external collaborations.

**Research Interests**

His research interests include the discovery of small-molecule drugs for CNS disorders and the design and synthesis of novel alicyclic building blocks for medicinal chemistry.